Prothena To Participate In Oppenheimer And RBC Capital Markets Healthcare Investor Conferences
DUBLIN, Ireland., Dec. 01, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior management team will participate in two upcoming investor meetings:
• Oppenheimer 26th Annual Healthcare Conference on December 8-9, 2015 in New York, NY. Prothena will present an update on its business on December 8th at 8:00 AM ET.
• RBC Capital Markets Healthcare Investor Day on December 10, 2015 in Denver, CO
A live webcast of the presentation from the Oppenheimer conference can be accessed through the investor relations section of the Company's website at www.prothena.com. Following the live presentation, replays of the webcasts will be available on the Company's website for at least 90 days following the presentation date.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. The company is developing antibody-based product candidates that target a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and psoriasis and other inflammatory diseases (PRX003).
For more information, please visit the company's web site at www.prothena.com.
• Oppenheimer 26th Annual Healthcare Conference on December 8-9, 2015 in New York, NY. Prothena will present an update on its business on December 8th at 8:00 AM ET.
• RBC Capital Markets Healthcare Investor Day on December 10, 2015 in Denver, CO
A live webcast of the presentation from the Oppenheimer conference can be accessed through the investor relations section of the Company's website at www.prothena.com. Following the live presentation, replays of the webcasts will be available on the Company's website for at least 90 days following the presentation date.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. The company is developing antibody-based product candidates that target a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and psoriasis and other inflammatory diseases (PRX003).
For more information, please visit the company's web site at www.prothena.com.